Results 211 to 220 of about 80,770 (310)

Strontium Incorporating Hypochlorous Acid as a Novel Conditioner for Improvement of Self‐Etch Adhesive Dentin Bond Performance

open access: yesNatural Sciences, Volume 6, Issue 2, April 2026.
ABSTRACT We developed a novel strontium‐incorporating hypochlorous acid (Sr/HOCl) conditioner to improve dental adhesive performance. Human dentin surfaces were pretreated with four protocols: untreated control, pure HOCl, HOCl with subsequent application of sulfinate agent (HOCl + SA), and Sr/HOCl.
Kittisak Sanon   +7 more
wiley   +1 more source

Electroactive Biodegradable Nerve Conduits Based on Alginate–Gelatine Polymer Matrix Modified With Inorganic Nanoparticles

open access: yesNatural Sciences, Volume 6, Issue 2, April 2026.
The effects of ZnO, fullerene C60 and polyaniline (PANI) nanoparticles in hybrid nerve conduits are explored. The composites show enhanced electrical conductivity, permeability to physiological fluids and mechanical stability. The biocompatibility of composites is confirmed by in vivo and in vitro studies.
Liudmyla Sukhodub   +7 more
wiley   +1 more source

Methodological Challenges of Emulating a Target Trial to Assess Effectiveness of Timing of PCSK9 Inhibitor Treatment Initiation Post Myocardial Infarction

open access: yesPharmacoepidemiology and Drug Safety, Volume 35, Issue 4, April 2026.
ABSTRACT Background Studies comparing treatment strategies based on initiation timing—such as starting PCSK9 inhibitor (PCSK9i) therapy sooner versus later after a myocardial infarction (MI)—are prone to immortal time bias. Clone‐censor‐weight methods can address these issues and allow the researcher to emulate a trial in which patients are assigned to
Thomas Cars   +13 more
wiley   +1 more source

Identification of a Highly Cooperative PROTAC Degrader Targeting GTP-Loaded KRAS(On) Alleles. [PDF]

open access: yesJ Am Chem Soc
Vetma V   +21 more
europepmc   +1 more source

Pharmacokinetic, Safety, and Immunogenicity Similarity of High‐ and Low‐Concentration Formulations of Adalimumab Biosimilar ABP 501, Adalimumab‐Atto

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 2, April 2026.
Consistent with previously demonstrated similarity of biosimilar ABP 501 (adalimumab‐atto) with adalimumab reference product, this study in healthy adults demonstrates the pharmacokinetic, safety, and immunogenicity similarity of a high‐concentration formulation (100 mg/mL) of ABP 501 with the original 50mg/mL formulation.
Vincent Chow   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy